Is Envoy Medical struggling financially?

Yes, by its own account. Envoy Medical told the SEC on 2 Apr 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Apr 2026

30/100

Fragile

Sector: Biotech/Pharma
Market cap: $57.9M
Source filing: DEF 14A 2 Apr 2026
Balance sheet: 30 Jun 2026

Cash runway

10months

If the burn speeds up

Empty by Apr 2027
15months

If it eases off

Empty by Sep 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$19.7M

Cash burned over the last 12 months

$18.4M

What Envoy Medical told the SEC

…qualified or modified as to uncertainty, audit scope, or accounting principles, except that each such report contained an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern. Furthermore, during each of the fiscal years ended December 31, 2025, and December 31, 2024 and through the March 25, 2026: (i) there were no “disagreements,” as that term is defined…

ENVOY MEDICAL, INC., Form DEF 14A, filed 2 Apr 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

305.4% share-count increase The company issued stock. Each share now owns 75.3% less of the business than a year ago, before any change in the price.
Cash burn is narrowing It is spending 41% less cash per year than it was, so the runway above is lengthening rather than shortening.

Cash runway

The runway math

What Envoy Medical told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt